Single-cell pharmacogenomics in stratified medicine
Speaker: Quin Wills, Mayo Clinic
Routine high content and high throughput genomics has now also become high resolution. This is, in part, thanks to microfluidic technologies lowering RNA sequencing costs to $30-$40 per cell. Commercially available whole-genome amplification is expected to become widely available by early 2014, while single-cell epigenomic, proteomic and metabolomic methods have also been published over the last two years. The growth of these approaches aimed at the fundamental unit of life are been touted as being as transformative as light microscopy was to 17th century biology. My talk will begin with a brief overview of developments and challenges in single-cell genomic science. I'll then discuss how, at Mayo Clinic, I'm exploiting 'noisy' gene expression in an attempt to better understand drug mechanisms. I'll conclude with work done at Oxford, together with Chris Holmes, testing the idea that single-cell genetics may explain differences in drug response that are otherwise hidden when averaging over many (even homogeneous) cells.